BOSTON SCIENTIFIC CORP
Boston Scientific CEO Michael F. Mahoney bought 186,240 shares on Aug. 3, 2026 at a weighted-average $48.34 per share, for about $9.0 million, according to an SEC Form 4. The purchase expands his holdings by about 13% to roughly 1.6 million shares. Shares traded around $48.43 at the Aug. 3 close.
Boston Scientific (BSX) director David C. Habiger bought 2,100 shares on Aug. 5, 2026, for about $100k, per an SEC Form 4. The weighted average purchase price was $47.59 per share, after which the stock closed at $47.74. BSX had fallen 54% over the prior 12 months, and Habiger’s direct holdings rose to 17,160 shares.
Habiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BSX (BOSTON SCIENTIFIC CORP). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BSX coverage spans insider activity, financial news and market movers.
In the last 30 days, BSX insiders filed 5 SEC Form 4 transactions — 5 purchases ($9.4M) and no sales. The most active reporter was Habiger David C with 3 filings.
The article discloses a fresh CEO open-market purchase, which can support near-term sentiment but is not a fundamental re-rating by itself.
The filing is a modest insider buy that may support near-term sentiment, but it is unlikely to change fundamentals by itself.
A director open-market purchase is a modest, sentiment-oriented signal but typically does not change fundamentals or near-term valuation by itself.
This is a routine insider buy with modest size and no stated catalyst beyond the disclosed transaction.
Insider open-market buying by the CEO is a modest positive sentiment signal, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions BSX with an AI model for sentiment and relevance, and aggregates insider trades from BOSTON SCIENTIFIC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Boston Scientific CEO Michael F. Mahoney bought 186,240 shares on Aug. 3, 2026 at a weighted-average $48.34 per share, for about $9.0 million, according to an SEC Form 4. The purchase expands his holdings by about 13% to roughly 1.6 million shares. Shares traded around $48.43 at the Aug. 3 close.
4 min readBoston Scientific (BSX) director David C. Habiger bought 2,100 shares on Aug. 5, 2026, for about $100k, per an SEC Form 4. The weighted average purchase price was $47.59 per share, after which the stock closed at $47.74. BSX had fallen 54% over the prior 12 months, and Habiger’s direct holdings rose to 17,160 shares.
4 min readHabiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.
2 min readHabiger David C purchased 1,182 shares of BOSTON SCIENTIFIC CORP (BSX) at an average of $48.13 ($48.07–$48.59) across 2 trades over 2026-08-03 to 2026-08-04.
1 min readMahoney Michael F (Chairman, President & CEO) purchased 186,240 shares of BOSTON SCIENTIFIC CORP (BSX) at $48.33 ($9.00M total) on 2026-08-03.
2 min readBoston Scientific (BSX) cut its 2026 guidance, lowering organic sales growth to 5% to 6% from 6.5% to 8% and adjusted EPS to $3.28 to $3.32 from $3.34 to $3.41. Management expects Q3 organic growth of 3% to 5% and only 0% to 25 bps operating-margin expansion. WATCHMAN demand weakened and U.S. electrophysiology lost share.
7 min readBoston Scientific (BSX) reported Q2 revenue of $5.44B vs $5.36B estimates and adjusted EPS of $0.86 vs $0.83. Management said Interventional Cardiology, Endoscopy and Neuromodulation grew, while Electrophysiology and WATCHMAN slowed. CEO Michael Mahoney cited U.S. WATCHMAN market changes and competition, leading to lower Q3 revenue guidance and reduced full-year adjusted EPS midpoint to $3.30.
6 min readThe FDA announced multiple Class I recalls and alerts involving medical devices and related products. Items include certain ventilators and introducer kits, reprocessed electrophysiology and ultrasound catheters by Medline Industries, heart pump controllers by Abiomed, Boston Scientific ACCOLADE pacemakers, and dialysis catheter kits involving Arrow International and Merit Medical. These actions may affect supply and compliance for healthcare providers and investors.
4 min readLUDWIG EDWARD J purchased 5,000 shares of BOSTON SCIENTIFIC CORP (BSX) at $45.48 ($0.23M total) on 2026-07-31.
1 min readBoston Scientific said its board approved a global restructuring plan on July 21, citing cost cuts and supply-chain optimization. The phased rollout runs from 2026 through late 2029, with estimated pre-tax costs of $700 million to $800 million and cash outflows of $600 million to $700 million. It projects about $500 million in annual savings once complete, while not specifying impacts in Costa Rica.
4 min read
